The incidence of cardiovascular diseases (CVD) in women, although lower than in men, increases dramatically after the menopause. Diabetes mellitus is a more powerful predictor of CHD risk and prognosis in women than in men. The aim of this study was to promote diet and physical activity (PA) regimen in order to decrease coronary risk in next years in postmenopausal women with impaired glucose tolerance. Methodological approach of this research is to compare data gathered trough prospective and retrospective analysis of anamnestic data, clinical research, diagnostic tests and biochemical parameters of 100 examinees, regarding the glycoregulation, lipid status, body mass indexes, incidence of hypertension, uric acid and fibrinogen level. The SCORE (Systematic Coronary Risk Evaluation) assessment system is derived from a large dataset of prospective European studies and predicts any kind of fatal CVD events over a ten-year period. It was documented that the then year risk of fatal CVD exerted a shift toward the lower percent value in postmenopausal women after proposed diet/PA regimen. In pre-menopausal women the estimated ten year risk of fatal CVD by SCORE was shifted toward the level below 1%. The risk of 15% and above was not documented after diet/physical activity regimen. The prevalence of the atherogenic lipid markers at the beginning and the end of the assay decreased for all investigated lipid parameters in the group of pre-menopausal women what was more than in postmenopausal ones. Presented data indicate that dietary regimen and physical activity are crucial factors in CVD prevention throughout menopause and beyond. Behavioral changes aimed at decreasing food intake and increasing energy expenditure, should be implemented in pre-menopausal period of life.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736108PMC
http://dx.doi.org/10.17305/bjbms.2007.3044DOI Listing

Publication Analysis

Top Keywords

physical activity
12
coronary risk
12
postmenopausal women
12
fatal cvd
12
diet physical
8
lipid status
8
score systematic
8
systematic coronary
8
risk evaluation
8
years postmenopausal
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Suven Life Sciences, Hyderabad, Telangana, India.

Background: Alzheimer's disease (AD) agitation is a distressing neuropsychiatric symptom characterized by excessive motor activity, verbal aggression, or physical aggression. Agitation is one of the causes of caregiver distress, increased morbidity and mortality, and early institutionalization in patients with AD. Current medications used for the management of agitation have modest efficacy and have substantial side effects.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Rush University Medical Center, Chicago, IL, USA.

Background: Alzheimer's disease is the most dreaded multifactorial neurological illness for which there is currently no known treatment. Although the exact cause of AD is still unknown, several factors related to lifestyle, genetics, and environment are known to have a significant role in the disease's development. Alzheimer's disease is characterized by neuronal loss, neurofibrillary tangles, and senile plaques.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Fleni, Buenos Aires, Buenos Aires, Argentina.

Background: The LatAm-FINGERS trial marks a pioneering initiative as the first non-pharmacological clinical trial encompassing participants from 12 Latin American countries, including Argentina, Brazil, Bolivia, Chile, Colombia, Costa Rica, Ecuador, Dominican Republic, Mexico, Peru, Puerto Rico, and Uruguay. This initiative represents a significant advancement in promoting inclusivity and diversity in clinical trial recruitment, particularly in underserved populations.

Method: The LatAm-FINGERS trial is a multicenter randomized clinical trial evaluating a lifestyle intervention tailored for the Latin American population.

View Article and Find Full Text PDF

Background: The effectiveness of multimodal lifestyle interventions to prevent dementia is being validated. Since a relatively long period (∼2 years) is required for manifesting an impact on cognitive function, the exploration of an alternative marker that exhibits changes within a comparatively brief duration, thereby prognosticating future alterations in cognitive function, is needed. The decline in gait function is associated with cognitive impairment and is also a predictor of future cognitive decline.

View Article and Find Full Text PDF

Background: Irisin is an exercise-induced myokine that elicits beneficial effects of exercise in fat, bone, and the brain. Previous work suggests that extracellular heat shock protein 90a (Hsp90a) mediates irisin-receptor interaction in bone and fat. Despite this, it remains unclear if Hsp90a is necessary for irisin signaling in the brain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!